neuropilin-1; vascular endothelial cell growth factor 165 receptor; CD304 (NRP1, NRP, VEGF165R)

Function: 1) membrane-bound isoform 1 a) receptor involved in - development of the cardiovascular system - angiogenesis - formation of certain neuronal circuits - organogenesis outside the nervous system b) mediates chemorepulsant activity of semaphorins c) binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF-165 isoform of VEGF & VEGF-B d) coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis e) may regulate VEGF-induced angiogenesis 2) soluble isoform 2 a) binds VEGF-165 & appears to inhibit its binding to cells b) may also induce apoptosis by sequestering VEGF-165 c) may bind various members of the semaphorin family d) expression has a negative impact on blood vessel number & integrity e) heterodimer with NRP2 (probable) f) binds PLXNB1 Structure: - belongs to the neuropilin family - contains 2 CUB domains - contains 2 F5/8 type C domains - contains 1 MAM domain Compartment: - cell membrane; single-pass type 1 membrane protein - isoform 2: secreted Alternative splicing: - named isoforms=2 Expression: - expression of isoforms 1 & 2 does not seem to overlap - isoform 1 is expressed by blood vessels of different tissues - in the developing embryo, it is found predominantly in the nervous system - in adult tissues, expressed in heart & placenta > lung, liver, skeletal muscle, kidney & pancreas > brain - isoform 2 is found in liver hepatocytes, kidney distal & renal proximal tubules

General

cluster-of-differentiation antigen; cluster designation antigen; CD antigen cell surface receptor glycoprotein phosphoprotein

Properties

SIZE: entity length = 923 aa MW = 103 kD COMPARTMENT: cellular membrane MOTIF: signal sequence {1-21} CUB domain {27-141} MOTIF: cysteine residue {C27} MODIFICATION: cysteine residue {C54} cysteine residue {C54} MODIFICATION: cysteine residue {C27} cysteine residue {C82} MODIFICATION: cysteine residue {C104} cysteine residue {C104} MODIFICATION: cysteine residue {C82} CUB domain {147-265} MOTIF: cysteine residue {C147} MODIFICATION: cysteine residue {C173} N-glycosylation site {N150} cysteine residue {C173} MODIFICATION: cysteine residue {C147} cysteine residue {C206} MODIFICATION: cysteine residue {C228} cysteine residue {C228} MODIFICATION: cysteine residue {C206} N-glycosylation site {N261} coagulation factors 5/8 type C domain (FA58C) {275-424} MOTIF: cysteine residue {C275} MODIFICATION: cysteine residue {C424} N-glycosylation site {N300} cysteine residue {C424} MODIFICATION: cysteine residue {C275} coagulation factors 5/8 type C domain (FA58C) {431-583} MOTIF: cysteine residue {C431} MODIFICATION: cysteine residue {C583} N-glycosylation site {N522} cysteine residue {C583} MODIFICATION: cysteine residue {C431} Ser glycosylation site {S612} MAM domain {645-811} MOTIF: cysteine residue {*1} (2) MODIFICATION: cysteine residue {*2} cysteine residue {*2} (2) MODIFICATION: cysteine residue {*1} N-glycosylation site {N842} transmembrane domain {857-879} Tyr phosphorylation site {Y920}

Database Correlations

OMIM 602069 UniProt O14786 PFAM correlations Entrez Gene 8829 Kegg hsa:8829

References

UniProt :accession O14786